Literature DB >> 22775589

Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study.

Boris Decourt1, Aaron Walker, Amanda Gonzales, Michael Malek-Ahmadi, Carolyn Liesback, Kathryn J Davis, Christine M Belden, Sandra A Jacobson, Marwan N Sabbagh.   

Abstract

To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22775589      PMCID： PMC4000702          DOI： 10.3109/09537104.2012.688899

Source DB:  PubMed          Journal:  Platelets        ISSN： 0953-7104            Impact factor:   3.862


  17 in total

Review 1.  Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.

Authors: 
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

2.  Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease.

Authors:  Kun Tang; Linda S Hynan; Fred Baskin; Roger N Rosenberg
Journal:  J Neurol Sci       Date:  2005-10-26       Impact factor: 3.181

3.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Authors:  R Vassar; B D Bennett; S Babu-Khan; S Kahn; E A Mendiaz; P Denis; D B Teplow; S Ross; P Amarante; R Loeloff; Y Luo; S Fisher; J Fuller; S Edenson; J Lile; M A Jarosinski; A L Biere; E Curran; T Burgess; J C Louis; F Collins; J Treanor; G Rogers; M Citron
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

Review 4.  Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.

Authors:  Alain Koyama; Olivia I Okereke; Ting Yang; Deborah Blacker; Dennis J Selkoe; Francine Grodstein
Journal:  Arch Neurol       Date:  2012-07

5.  Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease.

Authors:  F Colciaghi; E Marcello; B Borroni; M Zimmermann; C Caltagirone; F Cattabeni; A Padovani; M Di Luca
Journal:  Neurology       Date:  2004-02-10       Impact factor: 9.910

6.  Protease nexin-2/amyloid beta-protein precursor in blood is a platelet-specific protein.

Authors:  W E Van Nostrand; A H Schmaier; J S Farrow; D B Cines; D D Cunningham
Journal:  Biochem Biophys Res Commun       Date:  1991-02-28       Impact factor: 3.575

Review 7.  Molecular genetics of Alzheimer's disease: an update.

Authors:  Nathalie Brouwers; Kristel Sleegers; Christine Van Broeckhoven
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

8.  Immuno-electron microscopical demonstration of lysosomes in human blood platelets and megakaryocytes using anti-cathepsin D.

Authors:  J J Sixma; A van den Berg; A Hasilik; K von Figura; H J Geuze
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

9.  Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease.

Authors:  M Di Luca; L Pastorino; A Bianchetti; J Perez; L A Vignolo; G L Lenzi; M Trabucchi; F Cattabeni; A Padovani
Journal:  Arch Neurol       Date:  1998-09

10.  Platelets are the primary source of amyloid beta-peptide in human blood.

Authors:  M Chen; N C Inestrosa; G S Ross; H L Fernandez
Journal:  Biochem Biophys Res Commun       Date:  1995-08-04       Impact factor: 3.575
View more
  7 in total

1.  Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients.

Authors:  Jessyka Maria de França Bram; Leda Leme Talib; Helena Passarelli Giroud Joaquim; Tamires Alves Sarno; Wagner Farid Gattaz; Orestes Vicente Forlenza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-05-29       Impact factor: 5.270

2.  BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.

Authors:  Boris Decourt; Amanda Gonzales; Thomas G Beach; Michael Malek-Ahmadi; Aaron Walker; Lucia Sue; Douglas G Walker; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2013-03       Impact factor: 3.498

3.  MicroRNA-135b has a neuroprotective role via targeting of β-site APP-cleaving enzyme 1.

Authors:  Yi Zhang; Hongxia Xing; Shuangxi Guo; Zhiyong Zheng; Haoliang Wang; Dawei Xu
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

4.  Systematic Review of miRNA as Biomarkers in Alzheimer's Disease.

Authors:  S Swarbrick; N Wragg; S Ghosh; Alexandra Stolzing
Journal:  Mol Neurobiol       Date:  2019-02-08       Impact factor: 5.590

Review 5.  β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification.

Authors:  Harald Hampel; Simone Lista; Eugeen Vanmechelen; Henrik Zetterberg; Filippo Sean Giorgi; Alessandro Galgani; Kaj Blennow; Filippo Caraci; Brati Das; Riqiang Yan; Andrea Vergallo
Journal:  Alzheimers Res Ther       Date:  2020-10-16       Impact factor: 6.982

Review 6.  Platelets, a reliable source for peripheral Alzheimer's disease biomarkers?

Authors:  Michael Veitinger; Balazs Varga; Sheila B Guterres; Maria Zellner
Journal:  Acta Neuropathol Commun       Date:  2014-06-16       Impact factor: 7.801

7.  A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype.

Authors:  Michael Veitinger; Rudolf Oehler; Ellen Umlauf; Roland Baumgartner; Georg Schmidt; Christopher Gerner; Rita Babeluk; Johannes Attems; Goran Mitulovic; Eduard Rappold; John Lamont; Maria Zellner
Journal:  Acta Neuropathol       Date:  2014-09-24       Impact factor: 17.088
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.